Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Solid Tumour
Hallym University Medical CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the Solid Tumour cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Henlix, Inc | Phase 2 | B |
Atezolizumab Genentech, Inc. | Phase 2/3 | B |
ALECTINIB Cancer Research UK | Phase 2/3 | B |
Entrectinib Cancer Research UK | Phase 2/3 | B |
gsk1120212 Cancer Research UK | Phase 2/3 | B |
View all 36 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →